miR-aculous new avenues for cancer immunotherapy

Abstract

The rising toll of cancer globally necessitates ingenuity in early detection and therapy. In the last decade, the utilization of immune signatures and immune-based therapies has made significant progress in the clinic; however, clinical standards leave many current and future patients without options. Non-coding RNAs, specifically microRNAs, have been explored in pre-clinical contexts with tremendous success. MicroRNAs play indispensable roles in programming the interactions between immune and cancer cells, many of which are current or potential immunotherapy targets. MicroRNAs mechanistically control a network of target genes that can alter immune and cancer cell biology. These insights provide us with opportunities and tools that may complement and improve immunotherapies. In this review, we discuss immune and cancer cell–derived miRNAs that regulate cancer immunity and examine miRNAs as an integral part of cancer diagnosis, classification, and therapy.

Mapping the function of MicroRNAs as a critical regulator of tumor-immune cell communication in breast cancer and potential treatment strategies

“…Additionally, miRNAs improve the functionality of chimeric antigen receptor (CAR) T cells, which is crucial for adoptive cell therapy. The cytotoxicity and efficacy of CAR T cells are enhanced through the combination with specific miRNAs, as demonstrated by their ability to target EGFRvIII for glioblastoma or HER2 for cancer therapy ( Tang et al, 2022 ).…”